SSC
SRPT icon

Syverson Strege & Co’s Sarepta Therapeutics SRPT Stock Holding History

Syverson Strege & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8
Closed -$1.1K – 539
2023
Q1 		$1.1K Buy
+8
New +$1.04K ﹤0.01% 595

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Syverson Strege & Co's SRPT Position: Q2 2023 in Review

Syverson Strege & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 8 shares — an estimated $1.1K sold.

Syverson Strege & Co first reported a position in SRPT in Q1 2023 and held it in 1 quarter. The position peaked at $1.1K in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Syverson Strege & Co reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 8 Sarepta Therapeutics shares in Q2 2023, an estimated $1.1K.
  • Syverson Strege & Co first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 1 quarter.
  • Syverson Strege & Co's Sarepta Therapeutics position peaked at $1.1K in Q1 2023.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.